glp-1 drugs for parkinson's disease Receptor Agonists: A New Treatment in A Big Week for GLP-1

Very grateful for this product.

Owing to the short plasma half-life of GLP1, several GLP1 receptor agonists (GLP1RAs) were developed with different chemical structures and pharmacokinetic profiles for type 2 diabetes mellitus (T2DM) treatment

In vitro studies have also shown that BPA exposure causes molecular changes that initiate the development of cancers of the breast, prostate, and brain

Treatment of STZ-induced diabetic rats with another DPP-4 inhibitor, vildagliptin (10 mg/kg), significantly reduced plasma TNF- concentration and decreased nitric oxide concentration in serum and pancreatic homogenates compared with untreated diabetic rats [46]